In the Canadian NSCLC patient population, where EGFR testing only in patients with potential or diagnosed advanced non-squamous NSCLC has been the standard of care, the estimated incidence of EGFR mutations is 15% [8,9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.